Core Insights - Jazz Pharmaceuticals is set to present significant clinical and pre-clinical data at the 2026 American Association for Cancer Research (AACR) Annual Meeting, showcasing advancements in its oncology portfolio, particularly with zanidatamab, dordaviprone, and JZP898 [1][2][3] Group 1: Zanidatamab Developments - Zanidatamab is a HER2-targeted bispecific antibody that has shown meaningful benefits for adult patients with previously treated, unresectable or metastatic HER2+ biliary tract cancer [3][7] - The NeoZanHER trial data indicate that zanidatamab treatment resulted in a statistically significant decrease in tumor size and volume, with 30% of patients achieving pathologic complete response [4][5] - Presentations will explore zanidatamab's utility across HER2-expressing solid tumors and innovative biomarker-driven clinical trial designs [4] Group 2: Dordaviprone Insights - Dordaviprone, a protease activator and dopamine D2 receptor inhibitor, is being evaluated for its efficacy in renal cell carcinoma and small-cell lung cancer models [2][6] - Presentations will include data on the synergistic effects of dordaviprone in reducing renal cell carcinoma cell viability [6] Group 3: JZP898 Overview - JZP898 is an investigational, conditionally activated interferon alpha-2b cytokine pro-drug designed for activation within the tumor microenvironment, currently in Phase 1 development [2][34] - Preclinical data supporting JZP898's activity and immune engagement will be presented, highlighting its potential in solid tumors [4][6] Group 4: Regulatory Designations and Approvals - Zanidatamab has received multiple FDA designations, including Breakthrough Therapy and Fast Track designations for various indications, emphasizing its potential in treating HER2+ cancers [8] - The FDA granted accelerated approval for zanidatamab in treating unresectable or metastatic HER2-positive biliary tract cancer based on overall response rate and duration of response [7][8]